

Domenico Sergi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6529979/publications.pdf>

Version: 2024-02-01

39
papers

782
citations

471509

17
h-index

552781

26
g-index

39
all docs

39
docs citations

39
times ranked

1381
citing authors

#	ARTICLE	IF	CITATIONS
1	Triple positive breast cancer: A distinct subtype?. <i>Cancer Treatment Reviews</i> , 2015, 41, 69-76.	7.7	83
2	Emerging Biological Treatments for Uterine Cervical Carcinoma. <i>Journal of Cancer</i> , 2014, 5, 86-97.	2.5	51
3	Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 599-607.	2.5	39
4	Immunologic treatments for precancerous lesions and uterine cervical cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 29.	8.6	39
5	The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. <i>Oncotarget</i> , 2014, 5, 9619-9625.	1.8	35
6	“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016, 7, 17932-17944.	1.8	33
7	Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 119-123.	2.5	32
8	Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. <i>Journal of Hematology and Oncology</i> , 2015, 8, 53.	17.0	32
9	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. <i>Oncolmmunology</i> , 2016, 5, e1160187.	4.6	30
10	DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>International Journal of Cancer</i> , 2017, 140, 2587-2595.	5.1	30
11	Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 73-80.	2.5	24
12	FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 67.	8.6	22
13	Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. <i>Cancer Biology and Therapy</i> , 2017, 18, 339-346.	3.4	22
14	A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 39.	8.6	20
15	Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. <i>Gastric Cancer</i> , 2014, 17, 718-724.	5.3	20
16	Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 227-235.	2.5	19
17	Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 34.	8.6	18
18	Androgen receptor and antiandrogen therapy in male breast cancer. <i>Cancer Letters</i> , 2015, 368, 20-25.	7.2	17

#	ARTICLE	IF	CITATIONS
19	GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 1396-1401.	4.1	17
20	Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. <i>Scientific Reports</i> , 2017, 7, 10597.	3.3	16
21	Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 26.	8.6	15
22	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. <i>Oncotarget</i> , 2015, 6, 42773-42780.	1.8	14
23	Metformin and breast cancer: Basic knowledge in clinical context. <i>Cancer Treatment Reviews</i> , 2015, 41, 441-447.	7.7	13
24	Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>Journal of Translational Medicine</i> , 2018, 16, 22.	4.4	13
25	Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. <i>Journal of Cellular Physiology</i> , 2016, 231, 2541-2547.	4.1	12
26	Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin. <i>Journal of Cellular Physiology</i> , 2016, 231, 986-991.	4.1	12
27	Body mass index modifies the relationship between γ -H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. <i>BMC Cancer</i> , 2017, 17, 101.	2.6	12
28	Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. <i>Cancer Biology and Therapy</i> , 2018, 19, 328-334.	3.4	12
29	Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer. <i>Oncogenesis</i> , 2018, 7, 55.	4.9	12
30	The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression. <i>Oncolmmunology</i> , 2018, 7, e1457602.	4.6	11
31	DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. <i>PLoS ONE</i> , 2016, 11, e0149872.	2.5	11
32	p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. <i>Oncotarget</i> , 2014, 5, 10382-10392.	1.8	11
33	Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 132-142.	4.4	9
34	Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients. <i>Journal of Cancer</i> , 2014, 5, 398-405.	2.5	8
35	Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45 or younger: Evidence from a historic cohort. <i>Cancer Biology and Therapy</i> , 2016, 17, 470-476.	3.4	6
36	Anthropometric, Metabolic and Molecular Determinants of Human Epidermal Growth Factor Receptor 2 Expression in Luminal B Breast Cancer. <i>Journal of Cellular Physiology</i> , 2015, 230, 1708-1712.	4.1	5

#	ARTICLE	IF	CITATIONS
37	Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients. <i>Journal of Cancer</i> , 2016, 7, 516-522.	2.5	4
38	Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985319.	3.2	2
39	Docetaxel, oxaliplatin, and capecitabine (DOX) combination chemotherapy for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15065-e15065.	1.6	1